Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel vs Docetaxel in Neoadjuvant Breast Cancer
NCT05251766Phase 1Unknown
- Start
- Apr 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of paclitaxel in breast cancer (3 arms). Primary endpoint: Pathologic Complete Response Rate at 21 weeks. Status: unknown.
02
Drugs
paclitaxel
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05251766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05251766.